Sanofi snaps up acne vaccine developer Origimm Bio

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria's Origimm Biotechnology and its vaccine-based immunotherapy for people with acne.

Fishawack Health welcomes expert-led dermatology initiative ...

Patient and market insights from leading KOLs and life scien...

Insights from leading KOLs in new Dermatology eBook

Dupixent scores a first in rare skin disease prurigo nodular...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitatin

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

Incyte leads JAK push into eczema as FDA clears Opzelura cre...

The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US.